Precision BioSciences(DTIL)2024-11-04 12:15Financial Position - As of September 30, 2024, Precision BioSciences, Inc. expects to report approximately $121 million in cash, cash equivalents, and restricted cash[2]. - The financial results for the quarter ended September 30, 2024, are still under review by the independent registered public accounting firm, which may lead to changes in the reported figures[2]. - Forward-looking statements indicate expectations regarding cash balances, clinical development, and regulatory processes, but actual results may differ due to various risks and uncertainties[5]. Clinical Development - The company received clinical trial application (CTA) clearance in Moldova for its lead candidate, PBGENE-HBV, aimed at treating chronic hepatitis B[3]. - The acceptance of the CTA for the in vivo gene editing program PBGENE-HBV was announced on October 24, 2024[4].